FDA Says On October 3, FDA Amended The Emergency Use Authorization Of Novavax Covid-19 Vaccine, Adjuvanted To Include The 2023-2024 Formula; Novavax Covid-19 Vaccine, Adjuvanted Is No Longer Authorized For Use In U.S.
Portfolio Pulse from Benzinga Newsdesk
The FDA has amended the Emergency Use Authorization of Novavax's Covid-19 vaccine to include the 2023-2024 formula. However, the vaccine is no longer authorized for use in the U.S.
October 03, 2023 | 6:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The FDA's decision on Novavax's Covid-19 vaccine could have a minor impact on the broader market, represented by SPY.
While the FDA's decision could impact Novavax's stock, the effect on the broader market, represented by SPY, is likely to be minor given the diverse nature of the ETF.
CONFIDENCE 75
IMPORTANCE 50
RELEVANCE 50
NEGATIVE IMPACT
Novavax's Covid-19 vaccine is no longer authorized for use in the U.S., but the FDA has included the 2023-2024 formula in the EUA.
The FDA's decision to no longer authorize Novavax's Covid-19 vaccine for use in the U.S. could negatively impact the company's stock in the short term. However, the inclusion of the 2023-2024 formula in the EUA could potentially offset some of this impact.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100